NeoGenomics (NEO) “Buy” Rating Reaffirmed at First Analysis; The TP is Set to $23; TOMBSTONE EXPLORATION CORPORATION ORDINA (TMBXF) Shorts Down By 70.45%

NeoGenomics, Inc. (NASDAQ:NEO) Logo

Equity research analysts at First Analysis have $23 target price on NeoGenomics (NASDAQ:NEO). First Analysis’s target price would suggest a potential upside of 18.31% from the company’s stock close price. The rating was shown in an analyst note on Tuesday, 12 March.

TOMBSTONE EXPLORATION CORPORATION ORDINA (OTCMKTS:TMBXF) had a decrease of 70.45% in short interest. TMBXF’s SI was 15,600 shares in March as released by FINRA. Its down 70.45% from 52,800 shares previously. It closed at $0.0049 lastly. It is up 0.00% since March 13, 2018 and is . It has underperformed by 4.37% the S&P500.

Tombstone Exploration Corporation engages in the exploration, development, and production of mineral resource properties in the United States. The company has market cap of $3.27 million. The firm explores for silver and gold, as well as base minerals, including copper, lead, and zinc. It currently has negative earnings. It holds mineral rights in the Tombstone property covering an area of approximately 640 acres located in the Tombstone Mining district, Cochise County; and BLM lode claims comprising approximately 400 acres, including Stardust Mine located in the Eagletail Mining district, Yuma County, Arizona.

Among 4 analysts covering NeoGenomics (NASDAQ:NEO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NeoGenomics has $23 highest and $14 lowest target. $21’s average target is 8.02% above currents $19.44 stock price. NeoGenomics had 6 analyst reports since October 31, 2018 according to SRatingsIntel. The rating was maintained by Stephens with “Buy” on Wednesday, February 20. Needham maintained NeoGenomics, Inc. (NASDAQ:NEO) rating on Wednesday, February 20. Needham has “Buy” rating and $19 target. The stock of NeoGenomics, Inc. (NASDAQ:NEO) earned “Outperform” rating by Raymond James on Wednesday, October 31. First Analysis maintained the shares of NEO in report on Tuesday, March 12 with “Buy” rating.

Analysts await NeoGenomics, Inc. (NASDAQ:NEO) to report earnings on May, 7. They expect $0.02 earnings per share, 0.00% or $0.00 from last year’s $0.02 per share. NEO’s profit will be $1.89M for 243.00 P/E if the $0.02 EPS becomes a reality. After $0.04 actual earnings per share reported by NeoGenomics, Inc. for the previous quarter, Wall Street now forecasts -50.00% negative EPS growth.

The stock increased 1.99% or $0.38 during the last trading session, reaching $19.44. About 569,379 shares traded. NeoGenomics, Inc. (NASDAQ:NEO) has risen 126.03% since March 13, 2018 and is uptrending. It has outperformed by 121.66% the S&P500. Some Historical NEO News: 01/05/2018 – NeoGenomics 1Q Rev $63.4M; 20/03/2018 NeoGenomics Announces Executive Appointments; 20/03/2018 – NeoGenomics Names George Cardoza Pres of Pharma Services Division, Sharon Virag CFO; 16/05/2018 – NeoGenomics Forms Golden Cross: Technicals; 01/05/2018 – NeoGenomics Sees 2018 Loss/Shr 8c-Loss 13c; 01/05/2018 – NeoGenomics Backs 2018 Loss/Shr 13c-Loss 8c; 01/05/2018 – Detailed Research: Economic Perspectives on NeoGenomics, Illinois Tool Works, Carriage Services, Gorman-Rupp, Fiesta Restaurant; 20/03/2018 – NEOGENOMICS NAMES SHARON VIRAG CFO, CARDOZA HEAD OF PHARMA SVCS; 25/05/2018 – NeoGenomics to Participate In Two Upcoming Investor Conferences; 01/05/2018 – NeoGenomics Sees 2018 Adj EPS 15c-Adj EPS 20c

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. The company has market cap of $1.84 billion. It operates through Clinical Services and Pharma Services divisions. It has a 277.71 P/E ratio. The firm laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories.

More notable recent NeoGenomics, Inc. (NASDAQ:NEO) news were published by: Nasdaq.com which released: “Neon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update – Nasdaq” on March 11, 2019, also Seekingalpha.com with their article: “NeoGenomics Q4 2018 Earnings Preview – Seeking Alpha” published on February 18, 2019, Fool.com published: “Here’s Why Genetic Testing Stocks Rose as Much as 42.9% in February – Motley Fool” on March 11, 2019. More interesting news about NeoGenomics, Inc. (NASDAQ:NEO) were released by: Nasdaq.com and their article: “NeoGenomics (NEO) Reports Next Week: What to Know Ahead of the Release – Nasdaq” published on February 12, 2019 as well as Globenewswire.com‘s news article titled: “NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter – GlobeNewswire” with publication date: February 19, 2019.

NeoGenomics, Inc. (NASDAQ:NEO) Institutional Positions Chart